Risk of disability among adult leprosy cases and determinants of delay in diagnosis in five states of India: A case-control study.
Adolescent
Adult
Aged
Aged, 80 and over
Case-Control Studies
Delayed Diagnosis
/ statistics & numerical data
Disabled Persons
/ statistics & numerical data
Female
Humans
India
/ epidemiology
Leprosy
/ complications
Male
Middle Aged
Patient Acceptance of Health Care
/ statistics & numerical data
Risk Factors
Time-to-Treatment
/ statistics & numerical data
Young Adult
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
15
11
2018
accepted:
26
05
2019
revised:
10
07
2019
pubmed:
28
6
2019
medline:
27
11
2019
entrez:
28
6
2019
Statut:
epublish
Résumé
A high proportion of grade 2 disability (visible deformity) is indicative of delay in detection of leprosy and leprosy is one of the major causes of preventable disability. We conducted this study to determine the risk factors associated with disability (G2D and G1D) among adult new leprosy cases and to measure their strength of association. A multi-centric case-control study was undertaken in five states of India i.e. Andhra Pradesh, Delhi, Gujarat, Maharashtra and West Bengal). Among new adult patients, cases were defined as those with disability (G2D and G1D) at the time of diagnosis and controls were defined as those without any disability (G0D). Delays were quantified based on patient recall across a timeline. Patient delay defined as the time period between first noticed symptom by the patient and the first visit to any health care provider (HCP); HCP delay defined as the time period between patient's first visit to any HCP and the confirmation of diagnosis of leprosy; and total delay defined as the sum of both patient and HCP delays. A total of 1400 new leprosy patients (700 G2D/G1D and 700 G0D) across five states were interviewed. Among G2D/G1D, the median patient delay was 8 months compared with 4 months among G0D. The median HCP delay was 2 months for G2D/G1D and 1 month for G0D. The median total delay was 14 months for G2D/G1D and 6.2 months for G0D; observed median difference between groups was statistically significant (p<0.001). When patient delay was more than 3 months, odds of G2D/G1D at diagnosis were 1.6 times higher compared to when patient delay was less than 3 months. When the HCP delay was more than one month, the odds of G2D/G1D were 1.4 times higher compared to when the HCP delay was less than one month. When the patient had multi-bacillary type leprosy the odds of G2D/G1D at the time of diagnosis was nine times higher compared to pauci-bacillary type leprosy. Patient delay is the major reason for risk of disability (G2D/G1D) among adult leprosy patients. A patient delay of more than 3 months from the notice of first symptom is a significant indicator for the disabilities among adult leprosy patients. Early case detection campaigns like active surveys in endemic spots should be done periodically as this can reduce delays and promote early diagnosis. Additionally, the program should lay greater emphasis on raising community awareness regarding the disease. Also, health care provider delay of more than 1 month have been significant risk factors for disability among adult leprosy cases. Hence, periodical capacitation of all HCPs including private practitioners would significantly contribute to reduce diagnostic delay and promote timely referral and early detection.
Identifiants
pubmed: 31247040
doi: 10.1371/journal.pntd.0007495
pii: PNTD-D-18-01773
pmc: PMC6619834
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007495Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Indian J Lepr. 2012 Apr-Jun;84(2):123-9
pubmed: 23236699
Lepr Rev. 2015 Sep;86(3):283-7
pubmed: 26665365
Rev Soc Bras Med Trop. 2010 Jan-Feb;43(1):19-22
pubmed: 20305962
PLoS Negl Trop Dis. 2018 Sep 25;12(9):e0006808
pubmed: 30252851
Lepr Rev. 2000 Dec;71(4):511-6
pubmed: 11201907
PLoS Negl Trop Dis. 2017 Jan 12;11(1):e0005192
pubmed: 28081131
Indian J Lepr. 2014 Jul-Sep;86(3):111-6
pubmed: 26118223
Int J Lepr Other Mycobact Dis. 1998 Mar;66(1):1-9
pubmed: 9614833
PLoS Negl Trop Dis. 2016 Mar 15;10(3):e0004542
pubmed: 26977811
Lepr Rev. 2010 Dec;81(4):299-305
pubmed: 21313975
Ethiop J Health Sci. 2015 Oct;25(4):313-20
pubmed: 26949295
Lepr Rev. 2003 Dec;74(4):349-56
pubmed: 14750580
PLoS One. 2009 Dec 18;4(12):e8351
pubmed: 20020051
Trop Med Int Health. 2018 Feb;23(2):193-198
pubmed: 29230912
Indian J Dermatol Venereol Leprol. 2012 May-Jun;78(3):328-34
pubmed: 22565433
Lepr Rev. 2005 Mar;76(1):35-47
pubmed: 15881034
Wkly Epidemiol Rec. ;92(35):501-19
pubmed: 28861986
Lepr Rev. 2003 Sep;74(3):249-58
pubmed: 14577470
Indian J Lepr. 2006 Jul-Sep;78(3):261-7
pubmed: 17120509
Lepr Rev. 2003 Dec;74(4):366-73
pubmed: 14750582
Rev Inst Med Trop Sao Paulo. 2018;60:e27
pubmed: 29972464
Glob Health Action. 2016 Nov 23;9:32962
pubmed: 27885973